Exciting news for Biogen!
Today, Biogen completed the acquisition of immune-mediated disease company HI-Bio. Learn more about the acquisition: https://ow.ly/uVKJ50StGbo
Skip to main content
Exciting news for Biogen!
Today, Biogen completed the acquisition of immune-mediated disease company HI-Bio. Learn more about the acquisition: https://ow.ly/uVKJ50StGbo
To view or add a comment, sign in
Increasing numbers of IPF studies and a limited pipeline of participants mean researchers need novel strategies for drug development. Learn how to navigate the changing landscape of research on this rare disease in this blog from our experts. https://ow.ly/VVtR50SwIri
To view or add a comment, sign in
Save the date—there's an upcoming virtual meeting for people living with rare diseases, like scleroderma, to discuss the development of therapeutics. 💻 On December 14, 2023 from 12:00 - 5:00 PM ET, the FDA in collaboration with the Duke-Robert J. Margolis, MD Center for Health Policy will be hosting a virtual public meeting. The purpose of this meeting is "to discuss opportunities for engaging the rare disease patient community. This engagement can help inform the development of therapeutics to treat rare diseases and conditions." For more information about discussion topics, speaker bios, and how to register, visit: https://bit.ly/3ReQlp5 #scleroderma #raredisease #virtualmeeting #sayscleroderma #srfcure
To view or add a comment, sign in
𝗘𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗦𝗽𝗲𝗮𝗸𝗲𝗿 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄𝘀 Amit Sharma and Samvel Gasparyan discussed the transformations in the kidney disease treatment landscape over the past year, emphasizing notable breakthroughs and persistent obstacles faced by the #CKD field. You can read the full interviews here: https://ter.li/media-hub Join Amit and Samvel, alongside 200+ biopharma stakeholders, KOLs and regulators at the definitive 𝟲𝘁𝗵 𝗖𝗞𝗗 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 to collaboratively advance the frontier of more personalized, efficacious therapies for rare and common kidney disease.
To view or add a comment, sign in
If you are planning rare disease research, this webinar recording is a must see. Learn how early market-access evidence planning for your orphan drug can help gather the right evidence for reimbursement and access - the first time. View now. http://ow.ly/twtw50J9VHv #marketaccess #drugdevelopment
To view or add a comment, sign in
This great read outlines the role of RWE in clinical development. For geneticists operating in the age of growing multi-omics repositories, RWE presents a platform to fine-tune genotype-phenotype matching. Thanks Tsitsi Monera-Penduka, PhD!
Disease registries are a valuable source of real-world data across the drug development process. In our latest blog, we share some insights from our experiences with building disease registries. https://bit.ly/3QVJdxq #registries #RWD
To view or add a comment, sign in
Real-world evidence (RWE) is currently a buzzword in the pharmaceutical industry. Here is an overview of RWE's value throughout the entire product life cycle from Tsitsi Monera-Penduka, PhD ##rwe #realworldevidence #realworlddata
Disease registries are a valuable source of real-world data across the drug development process. In our latest blog, we share some insights from our experiences with building disease registries. https://bit.ly/3QVJdxq #registries #RWD
To view or add a comment, sign in
ICT Spring 2024 is now live! ☀️ Featuring insights in Decentralised Clinical Trials, Orphan Drug and Rare Disease Trials, and much more! Read here: https://bit.ly/3URlpxX #ClinicalTrials #decentralisedclinicaltrials #rarediseases #orphandrugs #pharmaceuticalindustry
ICT Spring 2024 is now live! ☀️ Featuring insights in Decentralised Clinical Trials, Orphan Drug and Rare Disease Trials, and much more! Read here: https://bit.ly/3URlpxX #ClinicalTrials #decentralisedclinicaltrials #rarediseases #orphandrugs #pharmaceuticalindustry
To view or add a comment, sign in
ICT Spring 2024 is now live! ☀️ Featuring insights in Decentralised Clinical Trials, Orphan Drug and Rare Disease Trials, and much more! Read here: https://bit.ly/3URlpxX #ClinicalTrials #decentralisedclinicaltrials #rarediseases #orphandrugs #pharmaceuticalindustry
To view or add a comment, sign in
Diagnostic sales specialist - Helping you accelerate the development and commercialization of diagnostic assays and kits
Article | What’s hot in molecular diagnostics and where it’s going Staying informed on the latest trends in molecular-diagnostics is key to staying ahead in the fight against disease. Read our blog to find out what’s hot in molecular-diagnostics, and where we are taking it. https://lnkd.in/dUHXesMb #diagnostics #immunodiagnostics #lifesciences #biopharma
To view or add a comment, sign in
Celltrion's infliximab biosimilar, CT-P13, was found to be just as effective and safe as the original brand name drug. This means a potentially more affordable option for treating patients with Crohn disease! Click the link to read more about the results found in a retrospective, real-world study in Japan. https://lnkd.in/eXUZDwp5
To view or add a comment, sign in